390 related articles for article (PubMed ID: 8283961)
41. Simultaneous expression of Borrelia OspA and OspC and IgM response in cerebrospinal fluid in early neurologic Lyme disease.
Schutzer SE; Coyle PK; Krupp LB; Deng Z; Belman AL; Dattwyler R; Luft BJ
J Clin Invest; 1997 Aug; 100(4):763-7. PubMed ID: 9259573
[TBL] [Abstract][Full Text] [Related]
42. Serodiagnosis of Lyme borreliosis by western immunoblot: reactivity of various significant antibodies against Borrelia burgdorferi.
Ma B; Christen B; Leung D; Vigo-Pelfrey C
J Clin Microbiol; 1992 Feb; 30(2):370-6. PubMed ID: 1537905
[TBL] [Abstract][Full Text] [Related]
43. Use of recombinant OspC from Borrelia burgdorferi for serodiagnosis of early Lyme disease.
Padula SJ; Dias F; Sampieri A; Craven RB; Ryan RW
J Clin Microbiol; 1994 Jul; 32(7):1733-8. PubMed ID: 7929767
[TBL] [Abstract][Full Text] [Related]
44. Improved Serodiagnostic Performance for Lyme Disease by Use of Two Recombinant Proteins in Enzyme-Linked Immunosorbent Assay Compared to Standardized Two-Tier Testing.
Bradshaw GL; Thueson RK; Uriona TJ
J Clin Microbiol; 2017 Oct; 55(10):3046-3056. PubMed ID: 28768731
[TBL] [Abstract][Full Text] [Related]
45. Comparative evaluation of two enzyme linked immunosorbent assay methods and three Western Blot methods for the diagnosis of culture-confirmed early Lyme borreliosis in Italy.
Marangoni A; Sparacino M; Mondardini V; Cavrini F; Storni E; Donati M; Cevenini R; Sambri V
New Microbiol; 2005 Jan; 28(1):37-43. PubMed ID: 15782625
[TBL] [Abstract][Full Text] [Related]
46. Application of multiplexing technology to the analysis of the intrathecally released immunoglobulins against B. burgdorferi antigens in neuroborreliosis.
Zajkowska J; Lelental N; Kulakowska A; Mroczko B; Pancewicz S; Bucki R; Kornhuber J; Lewczuk P
Immunol Lett; 2015 Nov; 168(1):58-63. PubMed ID: 26210581
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of in vivo expressed Borrelia burgdorferi antigens for improved IgM serodiagnosis of early Lyme disease.
Brandt KS; Ullmann AJ; Molins CR; Horiuchi K; Biggerstaff BJ; Gilmore RD
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):196-202. PubMed ID: 30344068
[TBL] [Abstract][Full Text] [Related]
48. The Performance of Nine Commercial Serological Screening Assays for the Diagnosis of Lyme Borreliosis: a Multicenter Modified Two-Gate Design Study.
Hoeve-Bakker BJA; Jonker M; Brandenburg AH; den Reijer PM; Stelma FF; van Dam AP; van Gorkom T; Kerkhof K; Thijsen SFT; Kremer K
Microbiol Spectr; 2022 Apr; 10(2):e0051022. PubMed ID: 35297658
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic and biological significance of anti-p41 IgM antibodies against Borrelia burgdorferi.
Ulvestad E; Kanestrøm A; Sønsteby LJ; Jureen R; Omland T; Edvardsen B; Lundervik J; Kristoffersen E; van Dam AP
Scand J Immunol; 2001 Apr; 53(4):416-21. PubMed ID: 11285123
[TBL] [Abstract][Full Text] [Related]
50. Serum antibodies against Borrelia afzelii, Borrelia burgdorferi sensu stricto and the 41-kiloDalton flagellin in patients from a Lyme borreliosis endemic area: analysis by EIA and immunoblot.
Nilsson I; von Rosen IA
APMIS; 1996 Dec; 104(12):907-14. PubMed ID: 9048870
[TBL] [Abstract][Full Text] [Related]
51. [Clinical manifestation of Lyme borreliosis in children with positive and negatiwe western blot results].
Ołdak E; Rozkiewicz D; Sulik A
Przegl Epidemiol; 2008; 62 Suppl 1():77-82. PubMed ID: 22320039
[TBL] [Abstract][Full Text] [Related]
52. Microbiological diagnosis in Lyme borreliosis.
Wilske B
Int J Med Microbiol; 2002 Jun; 291 Suppl 33():114-9. PubMed ID: 12141735
[TBL] [Abstract][Full Text] [Related]
53. Effects of adequate versus inadequate treatment of cutaneous manifestations of Lyme borreliosis on the incidence of late complications and late serologic status.
Plörer A; Sepp N; Schmutzhard E; Krabichler S; Trobos S; Schauer G; Pahl C; Stöffler G; Fritsch P
J Invest Dermatol; 1993 Feb; 100(2):103-9. PubMed ID: 8429231
[TBL] [Abstract][Full Text] [Related]
54. Concordance of four commercial enzyme immunoassay and three immunoblot formats for the detection of Lyme borreliosis antibodies in human serum: the two-tier approach remains.
Dickeson DJ; Chen SC; Sintchenko VG
Pathology; 2016 Apr; 48(3):251-6. PubMed ID: 27020501
[TBL] [Abstract][Full Text] [Related]
55. Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis.
Marangoni A; Moroni A; Accardo S; Cevenini R
Eur J Clin Microbiol Infect Dis; 2008 May; 27(5):349-54. PubMed ID: 18197445
[TBL] [Abstract][Full Text] [Related]
56. Polymerase chain reaction in diagnosis of Borrelia burgdorferi infections and studies on taxonomic classification.
Lebech AM
APMIS Suppl; 2002; (105):1-40. PubMed ID: 11985118
[TBL] [Abstract][Full Text] [Related]
57. Comparison of immunodot and western blot assays for diagnosing Lyme borreliosis.
Fawcett PT; Rosé CD; Gibney KM; Doughty RA
Clin Diagn Lab Immunol; 1998 Jul; 5(4):503-6. PubMed ID: 9665957
[TBL] [Abstract][Full Text] [Related]
58. [Comparison of EIA Borrelia recombinant IgM of the 3rd generation with EIA test based on whole cell antigen in the diagnosis of Lyme borreliosis].
Krbková L; Stroblová H
Klin Mikrobiol Infekc Lek; 2004 Dec; 10(6):271-8. PubMed ID: 15655723
[TBL] [Abstract][Full Text] [Related]
59. Immunoglobulin M capture assay for serologic confirmation of early Lyme disease: analysis of immune complexes with biotinylated Borrelia burgdorferi sonicate enhanced with flagellin peptide epitope.
Brunner M; Stein S; Mitchell PD; Sigal LH
J Clin Microbiol; 1998 Apr; 36(4):1074-80. PubMed ID: 9542940
[TBL] [Abstract][Full Text] [Related]
60. Comparison of immunofluorescence assay (IFA) and LIAISON in patients with different clinical manifestations of Lyme borreliosis.
Cerar T; Ruzic-Sabljic E; Cimperman J; Strle F
Wien Klin Wochenschr; 2006 Nov; 118(21-22):686-90. PubMed ID: 17160608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
